Sector Expert: Peter Suzdak

Rexahn Pharmaceuticals Inc.

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has more than 25 years of diverse experience in the pharmaceutical industry, including holding several management positions. Most recently, Dr. Suzdak was chief scientific officer (CSO) of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was cofounder, CEO and CSO of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was president and CEO of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as senior vice president of research and development of Guilford Pharmaceuticals, which developed therapeutics and diagnostics for neurological diseases and cancer, and as director of neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Recent Interviews

Taking Multiple Shots on the Cancer Treatment Goal: Rexahn's Peter Suzdak (11/28/14)

Rexahn Pharmaceuticals Inc.'s cancer-fighting drug development platform is built on a theme that focuses on targets exclusive to tumor cells—the ultimate strategy in the silver-bullet theory of dealing with disease because it can increase efficacy while reducing off-target effects, including heart and liver toxicity. Moreover, lower toxicity enables higher drug doses, which could enhance the desired therapeutic effects. In this interview with The Life Sciences Report, Rexahn CEO Peter D. Suzdak, Ph.D. talks about his company's clinical-stage drug candidates, and links their mechanisms of action to the ultimate value proposition for owning company shares.

Due to permission requirements, not all quotes are shown.